Search
Keros Therapeutics Inc
KROSAdd to Watchlist
10.070USD
-0.150-1.47%
Close 07-31 16:00（ET）Quotes delayed by 15 min
199.30MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Keros Therapeutics Inc is 7.25, ranking 304 out of 385 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 35.00 and a low of 16.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
21.833
Target Price
+118.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Keros Therapeutics Inc
KROS
8
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Keros Therapeutics Inc's expected revenue for the next quarter?
Keros Therapeutics Inc's expected revenue is 807.14K.
What is Keros Therapeutics Inc's price target?
Analysts forecast that Keros Therapeutics Inc's price target is USD 22.50, with the highest forecast at USD 35.00 and the lowest forecast at USD 16.00.
How have Keros Therapeutics IncKROS's recent earnings per share performed?
The market expectation was USD -1.21, while Keros Therapeutics IncKROS's earnings per share (EPS) for the previous quarter was USD -0.87. EPS for the next quarter is expected at USD -1.34.
What is the analyst rating for Keros Therapeutics Inc?
Based on the ratings of Keros Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.